Role of Ivacaftor in Cystic Fibrosis Treatment

Mechanism of Action and Approved Indications

Ivacaftor functions as a CFTR potentiator that increases the opening probability of CFTR channels at the cell surface, enhancing ion flow through the channel 2
The FDA and European Medicines Agency have approved ivacaftor for treating cystic fibrosis patients with specific mutations, including Class III mutations and Class IV mutation R117H, demonstrating substantial improvements in lung function, quality of life, and reduction in exacerbations 1, 2, 3
When combined with tezacaftor, ivacaftor is approved for patients with F508del mutations, a type II mutation 4

Significant improvement in lung function in patients with CF has been observed with ivacaftor treatment 2
Ivacaftor has a beneficial impact on chronic rhinosinusitis, with documented improvement in rhinologic quality of life as measured by SNOT-20 2
Case reports show reversal of sinus disease with normalized CT findings and resolved sinus symptoms with ivacaftor treatment 2
Ivacaftor enhances the effect of certain antibiotics, including ciprofloxacin, and exhibits antibacterial properties itself 2
Ivacaftor normalizes intraflagellar transport protein (IFT88) localization in ciliated respiratory epithelial cells 2

Tezacaftor, a selective CFTR corrector, combined with ivacaftor has been approved for treatment of patients with F508del mutations, and facilitates cellular transport of CFTR, restoring the protein in the correct position on the cell surface 4

Further studies on combination therapy and specific effects on chronic rhinosinusitis in vivo are warranted, as ongoing research explores the potential use of ivacaftor in patients with other CFTR mutations 2